Cooper Companies (The) vs Medtronic
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Ramon CA contact lenses and fertility devices (NASDAQ: COO) $3.87B FY2024 revenue (+9%); CooperVision MiSight myopia management, CooperSurgical IVF consumables, competing with J&J Vision and Alcon.
About
The Cooper Companies, Inc. is a San Ramon, California-based medical device company — publicly traded on the NASDAQ (NASDAQ: COO) as an S&P 500 Health Care component — operating two segments: CooperVision (soft contact lenses for vision correction globally — the second-largest contact lens manufacturer worldwide) and CooperSurgical (fertility and women's health medical devices including IVF laboratory consumables, assisted reproductive technology products, and gynecological surgical instruments) through approximately 15,000 employees in 130 countries. In fiscal year 2024 (ending October 2024), Cooper Companies reported revenues of $3.87 billion (+9% organic growth), with CooperVision generating $2.56 billion from daily, biweekly, and monthly contact lens sales across sphere, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) lens categories, and CooperSurgical generating $1.31 billion from fertility clinic consumables and women's health surgical products. CEO Albert White has executed CooperVision's strategy of capturing the premium daily silicone hydrogel lens market: silicone hydrogel material (higher oxygen permeability improving eye health versus conventional hydrogel) commands a 20-30% price premium over conventional daily lenses, and Cooper's MyDay (premium daily silicone hydrogel) and clariti (value silicone hydrogel) brands compete across price tiers against Johnson & Johnson Vision's Acuvue Oasys and CIBA Vision's AIR OPTIX brands for the global market shift toward dailies — the fastest-growing contact lens modality as patients prefer the convenience and hygiene of discarding lenses after each day's wear.
World's largest medical device company with $32.4B FY2024 revenue; Hugo robotic surgery challenges Intuitive Surgical; MiniMed automated insulin system; Patient Monitoring spin-off 2024; NYSE: MDT.
About
Medtronic plc is the world's largest medical device company, founded in 1949 by Earl Bakken and Palmer Hermundslie in a Minneapolis, Minnesota garage—where Bakken invented the first wearable external pacemaker—and now incorporated in Ireland with operational headquarters in Dublin, trading on NYSE (MDT). The company generated approximately $32.4 billion in revenues for fiscal year 2024 (ending April 26, 2024) under CEO Geoff Martha, spanning cardiovascular, neuroscience, surgical, and diabetes therapy technologies. Medtronic's 2015 acquisition of Covidien for $49.9 billion—at the time the largest medical device merger in history—added surgical instruments, patient monitoring, and respiratory interventions while enabling Irish incorporation that reduced the company's effective tax rate. In 2024, Medtronic announced the spin-off of its Patient Monitoring & Respiratory Interventions segment as an independent company (NewCo), sharpening focus on higher-margin, high-growth therapy areas.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.